Ardent Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Ardent Health reported 3rd quarter revenue of $1.62 billion and adjusted EBITDA of $138 million.
- Adjusted admissions increased 2.9% year over year, compared with 2.3% in the first half of 2026; ER visits grew 1.7% year over year, versus a 1.5% decline in the first half.
- Surgery volumes decreased 1.9% in the 3rd quarter, 100 basis points better than in the 2nd quarter; about half of the decline reflected intentional rationalization of certain lower-margin service lines in targeted locations.
- Total salaries, wages, and benefits expense declined 4.3% year over year, representing 39.9% of revenue, an improvement of 300 basis points from the same period last year.
- Contract labor spend declined 45% year over year, and contract labor expense represented 2.0% of SW&B, compared with 3.5% a year ago.
- Professional fee expense growth moderated to 7.4% in the 3rd quarter, compared with 10.4% in the 2nd quarter and 12.9% in the 1st quarter; supply expense growth was 2.6% year over year.
- Ardent generated $122 million of operating cash flow in the 3rd quarter and $258 million year to date in 2026, up 5% from $247 million in the prior-year period.
- 3rd quarter capital expenditures were $49 million, and the company repurchased $11 million of stock; year-to-date repurchases totaled $24 million.
- Ardent ended the 3rd quarter with $766 million of cash, $1.1 billion of total debt outstanding, and $1 billion of total available liquidity.
- The company announced a definitive agreement to divest its Kansas hospital ownership to its joint venture partner at an accretive multiple of 11 times EBITDA; the transaction is expected to close in the 4th quarter and is expected to enhance the margin profile by 40 basis points.
- Urgent care visits increased 9%, imaging was up 4%, and physician visits grew 1% over prior year in the 3rd quarter; centralized patient logistics hub call volume increased 15% and accepted cases increased 9%.
- Ardent reduced physician referral leakage by 400 basis points, while self-scheduling appointments grew 15%, up from 5% in 2Q.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for joining us, and welcome to the Ardent Health third quarter 2026 earnings conference call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Dave Styblo, lead investor relations.
Dave, please go ahead. Thank you, operator, and welcome to Ardent Health's third quarter 2026 earnings conference call.
Joining me today is Ardent President and Chief Executive Officer Dave Caspers and Chief Financial Officer Alfred Lumsdaine. Dave and Alfred will provide prepared remarks, and then we will open the line to questions. Before I turn the call over to Dave, I want to remind everyone that today's discussion contains forward-looking statements about future business and financial expectations. Actual results may differ significantly from those projected in today's forward-looking statements due to various risks and uncertainties, including the risks described in our periodic reports filed with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to update our forward-looking statements. Further, this call will include the discussion of certain non-GAAP financial measures, including adjusted EBITDA.
Reconciliation of these measures to the closest GAAP financial measures is included in our quarterly earnings press release and supplemental earnings presentation, which were both issued yesterday evening after the market closed and are available at ardenthealth.com. With that, I will turn the call over to Dave.
Thank you and good morning. When we spoke with you last quarter, I outlined a clear set of priorities: deliver more consistent financial results, grow EBITDA, deploy capital effectively, and execute against our commitments in a way that creates long-term shareholder value. Underpinning that is sharper operational execution, continued advancement of our IMPACT program, and a relentless focus on the factors we can directly influence. Lastly, I indicated I would be performing a portfolio review to assess the long-term strategic fit of our assets. I am encouraged by the tangible progress we are making against those priorities. We delivered strong third quarter financial results that reflect improving fundamentals and disciplined execution. We generated adjusted EBITDA of $138 million, increased adjusted admissions by 2.9%, improved expenses, and produced $122 million of operating cash flow. Importantly, that progress was driven by areas we can directly influence, including our labor management.
Despite the inflationary environment, we reduced SWB by 4% year-over-year in the third quarter, which helps position the enterprise to produce durable earnings and sustainable performance improvement. Key volume metrics improved sequentially. Emergency room visit growth accelerated and admissions improved, which are positive signals for the top of our demand funnel. Meanwhile, the challenging surgical volumes we experienced earlier in the year trended better in the third quarter as we accelerated efforts to make it even easier for our patients to access care. At the same time, we continue to advance IMPACT program initiatives that are strengthening the enterprise for long-term success. We realized incremental savings in the third quarter and remain fully on track to achieve our target of at least $70 million this year. Additionally, our IMPACT program continues to drive greater efficiency while strengthening operational execution and consistency.
Our overall progress and momentum give us the confidence to raise the midpoint of our adjusted EBITDA guidance by 1.5%. During the third quarter, we also took action to optimize our portfolio. We announced a definitive agreement to divest our Kansas hospital ownership to our joint venture partner. We are proud of what that partnership accomplished since 2017, including stabilizing the campus, preserving access to care, and expanding services for the community. Additionally, we significantly improved the financial performance over the last decade. As I discussed last quarter, we are taking a disciplined approach to portfolio management, evaluating our assets based on their long-term strategic fit and ability to create shareholder value. Our portfolio review determined Kansas was not the right long-term fit for Ardent. Ultimately, we agreed to monetize the asset at an accretive multiple of 11 times EBITDA.
The transaction, which is expected to close in the fourth quarter, will enhance our margin profile by 40 basis points and give us flexibility to redeploy capital towards growth that generates long-term shareholder value. Taken together, our third quarter performance and recent strategic portfolio optimization demonstrate meaningful progress against the priorities I outlined. Importantly, all of those activities anchor back to executing on our three-part growth strategy, which we continue to execute on with rigor and discipline. I'll spend the rest of my time speaking to that progress. The first pillar of our growth strategy is operational excellence to strengthen margins. That work is guided by our IMPACT program, which is a multi-year strategic imperative to optimize operating and financial performance. It includes initiatives to enhance revenue and improve our cost structure through higher efficiencies.
These are squarely within our control and help drive greater standardization, staffing optimization, and improved patient flow. We realized $5 million of savings from IMPACT in 2025, and as I mentioned earlier, we expect at least $70 million this year. We continue to identify additional opportunities to extend those benefits over time. It's important to note that IMPACT is not simply about reducing expenses. It's about becoming more efficient and improving performance. It consists of redesigning work to streamline throughput and maximize return on existing assets. Virtual care and AI are enablers on this front. Our ambient technology partner allows our physicians to see more patients and ensure appropriate coding capture. Meanwhile, the enterprise rollout of our virtual care platform is expediting discharge time and improving safety, including for those with a high fall risk.
We are also strengthening our payer contracting capabilities through a more disciplined, data-driven approach focused on improving reimbursement rates, optimizing contract terms, enhancing revenue cycle yields, and building stronger, more sustainable payer relationships. The second pillar is strategic organic growth in our core business, where we are building on our leading positions in faster-growing mid-sized urban markets. We are using Capacity IQ to concentrate on growth in service lines where we see the greatest opportunity. This includes optimizing access, reducing leakage, shortening wait times, and making better use of all of our inpatient resources, operating rooms, imaging equipment, and ambulatory assets. The top end of our demand funnel remains healthy. During the third quarter, urgent care visits increased 9%, imaging was up 4%, and physician visits grew 1% over prior year. Augmenting that funnel is our centralized patient logistics hub, which we recently stood up to optimize placement and transfer activity.
During the third quarter, total call volume was up 15% and accepted cases increased 9%. Following softer 2Q volumes, we are encouraged by surgery trends that improved in the third quarter. We continue to focus on converting demand into procedures by making it even easier for patients to schedule and access care. Those efforts are gaining traction. During the quarter, we reduced physician referral leakage by 400 basis points, while self-scheduling appointments grew 15%, up from 5% in 2Q. Our third pillar is strategic capital deployment. Our priorities include reinvesting in the business to drive organic growth, disciplined M&A, and maintaining flexibility for other strategic activities. We operate from a position of strength, with over $750 million of cash and a conservative net leverage ratio of 2.5 times. We plan to deploy capital toward organic growth opportunities that strengthen our positions in mid-sized urban markets and that support care teams.
This work is guided by Capacity IQ. We are also applying data and consumer insights to better understand patient needs, strengthen patient acquisition and retention, and improve access to care. From an inorganic growth standpoint, we take a disciplined approach to M&A. Our criteria consists of identifying strong asset in a growing mid-sized market with significant opportunity to drive financial accretion, all while preserving balance sheet flexibility. We are encouraged by our M&A pipeline and thoughtfully evaluating opportunities that meet our strategic and financial criteria. As part of that, we are particularly interested in systems where we can enhance margin and optimize performance by leveraging our larger scale, purchasing power, and our operational expertise. In looking forward, I would underscore that executing on our three-part growth strategy is foundational.
Strong consistency is established over time and requires a disciplined operating cadence to advance three key elements of excellence: excellence in care, excellence in our culture, and excellence in our business. Our 25,000 team members and over 2,000 employed and affiliated providers are the foundation in everything we do. I want to thank them for the excellence and dedication they bring to patient care we deliver every day. They are the reason 72% of our hospitals earned an A or B safety grade from Leapfrog, well above the national average of 59%, and the reason 13 Ardent hospitals earned recognition in U.S. News & World Report's recent ranking of best hospitals. With that, I turn the call over to Alfred, who will provide additional detail on our third quarter financial performance.
Thanks, Dave, and good morning, everyone. Thank you for joining us on today's call. We reported third quarter revenue of $1.62 billion and adjusted EBITDA of $138 million, driven by strong execution and cost discipline. I am very pleased with this performance, which reflects significant progress against a number of key initiatives as we continue to focus on controlling the controllables. We view Q3 as a largely clean quarter. Accordingly, we believe these results provide a strong, durable base for growth as we finish 2026 and look ahead to next year. Importantly, we experienced improved sequential volumes in Q3, driven in part by our efforts to help patients access care both at the top and bottom of our demand funnel.
Adjusted admissions growth accelerated to 2.9% year-over-year, compared to 2.3% in the first half of 2026, and ER visits grew 1.7% year-over-year, which was an improvement from the 1.5% decline in the first half of the year. Additionally, admissions were up slightly in Q3 after declining 1% last quarter. Surgery trends improved as well, decreasing 1.9% in the third quarter, which was 100 basis points better than the performance in the second quarter. Consistent with our experience in Q2, about half of that surgical decline was due to our intentional rationalization of certain lower-margin service lines in targeted locations. As Dave mentioned, we have been executing on a number of initiatives to enhance utilization and reduce access barriers for our patients. We are addressing financial hurdles through payment plans, shortening the time it takes to see a physician, and pursuing other initiatives to optimize surgery conversions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
